Reaserch Advance on Bruton Tyrosine Kinase Inhibitors in the Treatment of B-Cell Tumors--Review.
10.7534/j.issn.1009-2137.2020.01.056
- Author:
Ting-Ting JI
1
;
Qiu-Ni CHEN
1
;
Shan-Dong TAO
1
;
Liang YU
2
,
3
Author Information
1. Department of Hematology, Huai'an First People's Hospital Affiliaed to Nanjing Medical University, Huai'an 223300, Jiangsu Province, China,Key laboratory of Hematology of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China.
2. Department of Hematology, Huai'an First People's Hospital Affiliaed to Nanjing Medical University, Huai'an 223300, Jiangsu Province, China,Key laboratory of Hematology of Nanjing Medical University, Nanjing 210009, Jiangsu Province, China,E-mail: yuliangha@
3. com.
- Publication Type:Journal Article
- From:
Journal of Experimental Hematology
2020;28(1):333-338
- CountryChina
- Language:Chinese
-
Abstract:
Abstract In recent years, development of the targeted drugs according to the biological characteristics of tumors have provided more treatment options for tumor patients. It was found that the overactivation or abnormality of B cell receptor (BCR) signal pathway closely related to the occurrence and development of various B cell tumors, such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). As a key kinase in the BCR pathway, BTK inhibitors have obvious anti-tumor effect when its activity is being inhibitered. Currently, BTK inhibitors developed include the first-generation Ibrutinib and the second-generation Acalabrutinib, which can be targeted at the inhibition of BTK and its downstream signaling pathway, and have important therapeutic value for a variety of B-cell tumors, such as CLL and partial non-Hodgkin's lymphoma (NHL). However, its side effects and drug-resistance also gradually emerged, effective drug combination therapy has shown a certain clinical activity. This reviews summarizes briefly the mechanism and status of BTK inhibitors in the treatment of various B-cell tumors.
